DBV Technologies Announces Combined General Meeting
DBV Technologies, a clinical-stage biopharmaceutical company developing treatments for food allergies, is gearing up for its Combined General Meeting. This event will take place at the company’s headquarters, with shareholders encouraged to participate.
Meeting Details and Pre-Meeting Protocols
The General Meeting is set for June 11, 2025, at 02:00 p.m. CEST. All shareholders are welcomed as DBV Technologies aims to foster engagement and transparency.
How to Access Information
To keep shareholders informed, detailed preparatory documents and the meeting agenda will be made available ahead of the meeting. The preliminary notice was published recently, highlighting the company's commitment to informing its investors in accordance with legal requirements.
Participation Process
Shareholders interested in receiving documentation about the meeting can request this information. The company has set a deadline for requests to ensure everyone has the necessary materials for an informed participation process.
Online Engagement: Webcasting the Meeting
For those unable to attend physically, DBV Technologies will provide a live webcast of the General Meeting. This initiative allows remote participation, enabling shareholders around the globe to engage with the company.
About DBV Technologies and Its Vision
Headquartered in Châtillon, France, with operations in the United States, DBV Technologies is on a mission to redefine the treatment of food allergies. The company focuses on its innovative Viaskin platform, which aims to transform the landscape of food allergy therapies through epicutaneous immunotherapy (EPIT™).
With millions affected by food allergies, DBV Technologies recognizes the critical need for effective treatments. The Viaskin method works by using the skin's immune systems to introduce small amounts of allergens to help patients build tolerance. The ongoing clinical trials indicate the company's dedication to addressing this pressing health issue.
Recent Developments
As the company advances its clinical trials, DBV Technologies remains committed to developing impactful solutions. Their programs, particularly aimed at young children with food allergies, continue to gain traction, showcasing potential benefits for families dealing with these severe conditions.
Investor and Media Contact Information
For more personalized inquiries about the upcoming General Meeting or other matters, shareholders and media representatives can reach out to the DBV Technologies team. Investor contact Katie Matthews and Media contact Angela Marcucci are available via email for further assistance.
Frequently Asked Questions
When is the Combined General Meeting of DBV Technologies?
The meeting will take place on June 11, 2025, at 02:00 p.m. CEST.
How can I participate in the General Meeting?
Shareholders can participate by attending in person or via a live webcast on the company’s official website.
What materials will be available for shareholders?
Preparatory documents, including the agenda and draft resolutions, will be accessible for shareholders prior to the meeting.
Who can I contact for more information?
For inquiries, you can contact investor relations through Katie Matthews or the media contact Angela Marcucci via their official emails.
What is DBV Technologies focused on?
DBV Technologies is dedicated to developing innovative treatments for food allergies using its proprietary Viaskin platform.
